About this trial
This study evaluates the safety and effectiveness of focused ultrasound spleen neuromodulation in patients with septic shock, a life-threatening condition characterized by excessive inflammation and organ dysfunction. The primary objective is to determine whether non-invasive, focused ultrasound stimulation of the spleen can reduce circulating inflammatory cytokine levels in this patient population.
Eligibility Criteria:
Adults aged 18 years or older Diagnosed with septic shock and admitted to the ICU within 24 hours Expected to require intensive care for at least 72 hours
Study Protocol:
Participants will be randomly assigned to one of two groups:
Intervention Group: Will receive standard septic shock care plus twice-daily focused ultrasound stimulation over the spleen for five days, using a portable device.
Control Group: Will receive standard septic shock care alone. Blood samples will be collected at baseline and Day 5 to measure inflammatory cytokine levels, including TNF-α, IL-1β, IL-6, and IL-10. Additional assessments will include lymphocyte subpopulations, organ function scores, ICU length of stay, 28-day mortality, and adverse events.
Outcome Measures:
Primary: Change in levels of inflammatory cytokines on Day 5. Secondary: Changes in organ function (SOFA score), ICU length of stay, 28-day survival, and safety/tolerability of the intervention.
Eligibility criteria
Qualifiers
Age ≥ 18 years, regardless of sex
Diagnosed with septic shock according to Sepsis-3 criteria: Sequential Organ Failure Assessment (SOFA) score ≥ 2 and requiring vasopressor support to maintain a mean arterial pressure (MAP) ≥ 65 mmHg.
Admitted to the ICU within 24 hours of septic shock diagnosis
Expected to require intensive care for at least 72 hours
Disqualifiers
Known pregnancy or breastfeeding
Participation in another interventional clinical trial within 30 days
Known immunodeficiency or ongoing immunosuppressive therapy
Malignancy with life expectancy < 6 months
Trial design
Treatments tested in this trial
- Focused Ultrasound Spleen Neuromodulation
Treatment groups
Sponsors and collaborators
First Affiliated Hospital of Wannan Medical College
Lead sponsor
Wuhu City Second People's Hospital
Collaborator